Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

Dr. Reddy's Laboratories (NVO) will launch its off-patent version of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy Ozempic in Canada within the “next few days,” becoming the first to sell a generic ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

See more of our coverage in your search results. Add The New York Post on Google The initial wave of a massive bloodbath at Oracle has begun to show up in public filings — with 700 workers expected to ...

Oracle has cut an unspecified number of jobs as the software giant looks to reduce costs and continue growing its artificial intelligence business, according to former employees and multiple reports.

Oracle is conducting a round of layoffs, two people familiar with the move told CNBC. The layoffs were in the thousands, the people said. The software maker has continued to increase spending on data ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

A revolution is coming in the U.S. generics marketplace, one that has the potential to transform savvy organizations into engines of growth, and to end the decades-long “race to the bottom” that for ...

A large majority of technology professionals in Southeast Asia are moving their companies away from Oracle’s Java software, driven by rising licensing costs and the need to free up budget for ...